Compare CDZI & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | PEPG |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | 25 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 353.9M |
| IPO Year | N/A | 2022 |
| Metric | CDZI | PEPG |
|---|---|---|
| Price | $4.93 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 473.0K | ★ 2.1M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.80 | N/A |
| Revenue Next Year | $125.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.13 | $0.89 |
| 52 Week High | $6.96 | $7.80 |
| Indicator | CDZI | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 18.76 |
| Support Level | $4.46 | $1.09 |
| Resistance Level | $5.81 | $5.46 |
| Average True Range (ATR) | 0.25 | 0.39 |
| MACD | 0.02 | -0.38 |
| Stochastic Oscillator | 54.74 | 10.17 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.